Access the full text.
Sign up today, get DeepDyve free for 14 days.
I. Schmidt, Johannes Blümel, H. Seitz, H. Willkommen, Johannes Löwer (2001)
Parvovirus B19 DNA in plasma pools and plasma derivativesVox Sanguinis, 81
Aubin (2000)
Large-scale screening for human parvovirus B19 DNA by PCR: application to the quality control of plasma for fractionationVox Sang, 78
B. Just, H. Lefèvre (2002)
Detection of parvovirus B19 DNA in solvent–detergent plasmaVox Sanguinis, 83
L. Jarvis (2002)
Response 12Vox Sanguinis, 82
F. Hayakawa, K. Imada, M. Towatari, H. Saito (2002)
Life‐threatening human parvovirus B19 infection transmitted by intravenous immune globulinBritish Journal of Haematology, 118
Mauser-Bunschoten (1998)
High prevalence of parvovirus B19 IgG antibodies among Dutch hemophilia patientsVox Sang, 74
A. Azzi, S. Ciappi, K. Zakvrzewska, M. Morfini, G. Mariani, P. Mannucci (1992)
Human parvovirus B19 infection in hemophiliacs first infused with two high‐purity, virally attenuated factor Vlll concentratesAmerican Journal of Hematology, 39
(2002)
Simultaneous blood donor screening of HCV-RNA and B19-DNA in Finland
K. Brown, N. Young, B. Alving, L. Barbosa (2001)
Parvovirus B19: implications for transfusion medicine. Summary of a workshopTransfusion, 41
Parvovirus B 19 : implications for
C. Prowse, T. Guillaume (1994)
Parvovirus B19 and blood productsThe Lancet, 343
J. Jongerius, M. Sjerps, H. Cuijpers, Harry A.J. Van Drimmelen, Cees L. Van der Poel, H. Reesink, M. Molijn, Geert A.H. Peeters, Ton P.W. Peeters, P. Lelie (2002)
Validation of the NucliSens Extractor combined with the AmpliScreen HIV version 1.5 and HCV version 2.0 test for application in NAT minipool screeningTransfusion, 42
E. Manaresi, G. Gallinella, E. Zuffi, F. Bonvicini, M. Zerbini, M. Musiani (2002)
Diagnosis and quantitative evaluation of parvovirus B19 infections by real‐time PCR in the clinical laboratoryJournal of Medical Virology, 67
Y. Laurian, E. Dussaix, A. Parquet, A. Chalvon-Demersay, R. d’Oiron, G. Tchernia (1994)
Transmission of human parvovirus B19 by plasma derived factor VIII concentrates.Nouvelle revue francaise d'hematologie, 36 6
F. Mcomish, P. Yap, A. Jordan, H. Hart, B. Cohen, P. Simmonds (1993)
Detection of parvovirus B19 in donated blood: a model system for screening by polymerase chain reactionJournal of Clinical Microbiology, 31
J. Saldanha, P. Minor (1996)
Detection of human parvovirus B19 DNA in plasma pools and blood products derived from these pools: implications for efficiency and consistency of removal of B19 DNA during manufactureBritish Journal of Haematology, 93
Anonymous (2002)
Human anti-D immunoglobulinPharmeurope, 14
Bunschoten, HL. Zaaijerb, Drimmelen, S. Vries, Roosendaal, HM. denBerg, RN. Lelieb (1998)
High Prevalence of Parvovirus B19 IgG Antibodies among Dutch Hemophilia PatientsVox Sanguinis, 74
Y. Yoto, T. Kudoh, K. Haseyama, N. Suzuki, Takanori Oda, T. Katoh, Tsuneo Takahashi, Sadami Sekiguchi, Shunzo Chiba (1995)
Incidence of human parvovirus B19 DNA detection in blood donorsBritish Journal of Haematology, 91
Claudia Aberham, Claudia Pendl, Patricia Gross, Gerold Zerlauth, M. Gessner (2001)
A quantitative, internally controlled real-time PCR Assay for the detection of parvovirus B19 DNA.Journal of virological methods, 92 2
R., Boom, '. SOL, C. Jansen, '. WERTHEIM-vAN, Dillen, J., van der, '. Noordaa (1990)
Rapid and simple method for purification of nucleic acidsJournal of Clinical Microbiology, 28
T. Weimer, S. Streichert, C. Watson, A. Gröner (2001)
High‐titer screening PCR: a successful strategy for reducing the parvovirus B19 load in plasma pools for fractionationTransfusion, 41
P. Daly, A. Corcoran, Bernard Mahon, Sean Doyle (2002)
High-Sensitivity PCR Detection of Parvovirus B19 in PlasmaJournal of Clinical Microbiology, 40
J. Aubin, C. Defer, M. Vidaud, M. Montreuil, B. Flan (2000)
Large–Scale Screening for Human Parvovirus B19 DNA by PCR: Application to the Quality Control of Plasma for FractionationVox Sanguinis, 78
Larry Anderson, C. Tsou, Robert Parker, Terence Chorba, H. Wulff, P. Tattersall, P. Mortimer (1986)
Detection of antibodies and antigens of human parvovirus B19 by enzyme-linked immunosorbent assayJournal of Clinical Microbiology, 24
E. Tabor, J. Epstein (2002)
NAT screening of blood and plasma donations: evolution of technology and regulatory policy *Transfusion, 42
Ulrike Koenigbauer, T. Eastlund, J. Day (2000)
Clinical illness due to parvovirus B19 infection after infusion of solvent/detergent‐treated pooled plasmaTransfusion, 40
C. Wittwer, Kirk Ririe, R. Andrew, D. David, R. Gundry, Ulysses Balis (1997)
The LightCycler: a microvolume multisample fluorimeter with rapid temperature control.BioTechniques, 22 1
J. Saldanha, N. Lelie, M. Yu, A. Heath (2002)
Establishment of the first World Health Organization International Standard for human parvovirus B19 DNA nucleic acid amplification techniquesVox Sanguinis, 82
Engelfriet Engelfriet, Reesink Reesink (2002)
Implementation of donor screening for infectious agents transmitted by blood by nucleic acid technologyVox Sang, 82
BACKGROUND: As of 2004, the European Pharmacopoeia demands that plasma pools for production of anti‐D immunoglobulin should not contain more than 104 IU per mL of parvovirus B19 (B19V) DNA. Hence, before pooling, highly viremic donations have to be identified, and after pooling the level of B19V DNA must be determined. The performance of a new real‐time B19V DNA PCR test (Roche, Mannheim, Germany) was studied, using a DNA extractor (NucliSens, bioMerieux, Boxtel, the Netherlands) for isolation of nucleic acid, and using a DNA quantification test (LightCycler apparatus, Roche, Mannheim, Germany) for amplification and detection. STUDY DESIGN AND METHODS: Dilutions of the international B19V DNA standard and reference preparations were tested to determine the precision, linear range, and accuracy of the assay and to calculate the factor for conversion of B19V DNA copies to IUs. The internal control signals, invalid test results, and the effect of cryo‐poor plasma were studied as a measure for robustness. Routine performance was assessed by testing 164 manufacturing pools (not screened for B19V) and 1048 test pools of 480 donations each. RESULTS: The copies‐to‐IU conversion factor was calculated to be 3.34 (95% CI, 3.07‐3.63). The assay appears linear between 103 and 107 IU per mL. Between 103 and 105 IU per mL, the test can discriminate samples differing a factor two in B19V DNA content. Overall, 0.78 percent of the test results were invalid. Of 127 B19V DNA negative control plasma samples, 7 were contaminated with low levels of B19V DNA. Of 164 nonscreened manufacturing plasma pools, 92 contained B19V DNA (56%); 13 contained more than 104 IU per mL. Of 503,040 donations, 29 contained more than 5 × 106 IU per mL B19V DNA (1:17,346). CONCLUSION: The B19V DNA quantification test (LightCycler, Roche ) is suitable for quantitative, routine, in‐process measurement of B19V DNA levels in plasma pools, using the DNA extractor (NucliSens, bioMerieux) for nucleic acid isolation.
Transfusion – Wiley
Published: Jan 1, 2004
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.